Sentiment-Signal
23,3
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 28.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 30.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 27.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 13.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 10.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
Stammdaten
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Unternehmen & Branche
| Name | Pacira BioSciences, Inc. |
|---|---|
| Ticker | PCRX |
| CIK | 0001396814 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,09 Mrd. USD |
| Beta | 0,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 726,411,000 | 7,034,000 | 0.16 | 1,264,917,000 | 693,111,000 |
| 2025-09-30 | 10-Q | 179,516,000 | 5,432,000 | 0.12 | 1,297,577,000 | 727,214,000 |
| 2025-06-30 | 10-Q | 181,099,000 | -4,847,000 | -0.11 | 1,537,262,000 | 757,767,000 |
| 2025-03-31 | 10-Q | 168,923,000 | 4,812,000 | 0.10 | 1,586,669,000 | 798,541,000 |
| 2024-12-31 | 10-K | 700,966,000 | -99,560,000 | -2.15 | 1,553,516,000 | 778,348,000 |
| 2024-09-30 | 10-Q | 168,573,000 | -143,466,000 | -3.11 | 1,521,691,000 | 749,583,000 |
| 2024-06-30 | 10-Q | 178,023,000 | 18,886,000 | 0.39 | 1,646,820,000 | 879,278,000 |
| 2024-03-31 | 10-Q | 167,117,000 | 8,979,000 | 0.19 | 1,583,321,000 | 892,162,000 |
| 2023-12-31 | 10-K | 674,978,000 | 41,955,000 | 0.89 | 1,574,386,000 | 870,130,000 |
| 2023-09-30 | 10-Q | 163,926,000 | 10,858,000 | 0.23 | 1,534,462,000 | 831,551,000 |
| 2023-06-30 | 10-Q | 169,467,000 | 25,763,000 | 0.51 | 1,542,381,000 | 807,975,000 |
| 2023-03-31 | 10-Q | 160,341,000 | -19,536,000 | -0.43 | 1,523,418,000 | 768,041,000 |
| 2022-12-31 | 10-K | 666,823,000 | 15,909,000 | 0.34 | 1,681,200,000 | 775,010,000 |
| 2022-09-30 | 10-Q | 167,466,000 | -693,000 | -0.02 | 1,734,365,000 | 770,123,000 |
| 2022-06-30 | 10-Q | 169,411,000 | 19,876,000 | 0.40 | 1,733,988,000 | 756,636,000 |
| 2022-03-31 | 10-Q | 157,991,000 | 6,828,000 | 0.15 | 1,891,476,000 | 709,576,000 |
| 2021-12-31 | 10-K | 541,533,000 | 41,980,000 | 0.92 | 2,075,353,000 | 730,408,000 |
| 2021-09-30 | 10-Q | 127,722,000 | 17,660,000 | 0.39 | 1,356,002,000 | 718,602,000 |
| 2021-06-30 | 10-Q | 135,590,000 | 19,081,000 | 0.42 | 1,325,833,000 | 687,168,000 |
| 2021-03-31 | 10-Q | 119,027,000 | 10,369,000 | 0.23 | 1,287,549,000 | 650,818,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Cross Shawn | Officer, Chief Financial Officer | Open Market Sale | -12,941 | 25.16 | -325,595.56 | -161,0% | |
| 2026-04-22 | Cross Shawn | Officer, Chief Financial Officer | Open Market Sale | -1,500 | 25.01 | -37,515.00 | -18,5% | |
| 2026-04-21 | Cross Shawn | Officer, Chief Financial Officer | Open Market Sale | -2,845 | 25.01 | -71,153.45 | -35,2% | |
| 2026-04-20 | Cross Shawn | Officer, Chief Financial Officer | Open Market Sale | -7,714 | 25.14 | -193,929.96 | -95,9% | |
| 2025-12-10 | Cross Shawn | Officer, Chief Financial Officer | Open Market Sale | -9,104 | 25.14 | -228,874.56 | -113,1% | |
| 2025-12-09 | Cross Shawn | Officer, Chief Financial Officer | Open Market Sale | -15,896 | 25.03 | -397,876.88 | -196,7% | |
| 2025-11-10 | Cross Shawn | Officer, Chief Financial Officer | Open Market Sale | -12,060 | 22.09 | -266,405.40 | -131,7% | |
| 2025-09-04 | Ceesay Abraham | Director | Open Market Sale | -2,354 | 27.19 | -64,005.26 | -31,6% | |
| 2025-08-07 | BIGAL MARCELO | Director | Open Market Sale | -4,912 | 23.67 | -116,267.04 | -57,5% | |
| 2025-06-04 | RIKER LAUREN | Officer, Senior Vice President, Finance | Open Market Sale | -5,578 | 26.21 | -146,208.16 | -72,3% | |
| 2025-06-04 | WILLIAMS KRISTEN | Officer, Chief Administrative Officer | Open Market Sale | -14,376 | 26.24 | -377,226.24 | -186,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.